Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 1:30 p.m. ET.
A live webcast and 90-day replay will be available via Verrica’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
In the May 13 session, VRCA gained 3.08%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.8% during that session. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Clinical data update | Positive | +17.7% | Phase 2 VP‑315 data showing tumor reductions and potential abscopal effect. |
| May 05 | Earnings call date | Neutral | +12.6% | Announcement of Q1 2026 results date and corporate update webcast. |
| Apr 09 | Abstract acceptance | Positive | -12.3% | Late‑breaking abstract on VP‑315 abscopal effect accepted for SID meeting. |
| Apr 06 | Investor conference | Neutral | +9.3% | Participation in 25th Annual Needham Virtual Healthcare Conference. |
| Mar 11 | Earnings report | Positive | +4.7% | Strong 2025 revenue growth, SG&A cuts, no debt, and extended cash runway. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially clinical data and corporate updates, has often been followed by double‑digit moves, with both strong rallies and occasional sharp pullbacks.
Over the last six months, VRCA has combined steady corporate outreach with meaningful clinical and financial milestones. A March 11, 2026 earnings release highlighted strong 2025 revenue growth and cost cuts, followed by an April Needham conference appearance. In April and May 2026, multiple updates on VP‑315’s Phase 2 data and SID presentations emphasized potential abscopal effects in basal cell carcinoma. The latest investor conference participation fits this pattern of active engagement with the healthcare and investor community alongside ongoing clinical progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026
Event details:
Date: Tuesday, May 19, 2026
Time: 1:30pm ET
Location: NASDAQ
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
